Immune Financial Statements From 2010 to 2024
Immune Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Immune Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immune Pharmaceuticals financial statements helps investors assess Immune Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immune Pharmaceuticals' valuation are summarized below:Immune Pharmaceuticals does not presently have any fundamental trends for analysis.
This module can also supplement various Immune Pharmaceuticals Technical models . Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Check Immune Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immune main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Immune financial statements analysis is a perfect complement when working with Immune Pharmaceuticals Valuation or Volatility modules.
Immune |
Immune Pharmaceuticals OTC Stock Shares Outstanding Analysis
Immune Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Immune Pharmaceuticals Shares Outstanding | 72.38 M |
Most of Immune Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Immune Pharmaceuticals has 72.38 M of shares currently outstending. This is 59.91% lower than that of the Healthcare sector and 94.3% lower than that of the Drug Manufacturers - Major industry. The shares outstanding for all United States stocks is 87.34% higher than that of the company.
Immune Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immune Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Immune Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immune Pharmaceuticals competition to find correlations between indicators driving Immune Pharmaceuticals's intrinsic value. More Info.Immune Pharmaceuticals is currently regarded as number one stock in return on asset category among related companies. It is considered the number one company in current valuation category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immune Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immune Pharmaceuticals' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immune Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Pharmaceuticals' short interest history, or implied volatility extrapolated from Immune Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Immune OTC Stock
If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |